Latigo Biotherapeutics (LTGO) investor relations material

Executive summary

• Completed an upsized IPO in August 2026, raising $397.4 million in gross proceeds and $363.9 million in net proceeds, extending cash runway into 2029.

• Lead candidate onzotrigine showed strong efficacy in pivotal and Phase 2 trials for acute pain, outperforming opioid comparators, with rapid onset and opioid-sparing effects; Phase 3 trials are planned for late 2026 with topline results expected in 2027.

• LTG-321, a next-generation Na1.8 inhibitor for chronic musculoskeletal pain, is in Phase 2 with topline data expected in 2027; LTG-418 and other pipeline assets are in preclinical or discovery stages.

• Expanded leadership with the appointment of Naomi Lowy, M.D., as SVP of global regulatory affairs, bringing significant FDA experience.

Financial highlights

• Net loss for Q2 2026 was $25.8 million, nearly flat year-over-year; net loss for the first half of 2026 was $48.8 million, up from $46.8 million in 2025.

• Research and development expenses decreased to $21.2 million for Q2 2026 from $22.9 million in Q2 2025, mainly due to lower clinical trial costs.

• General and administrative expenses rose to $4.6 million in Q2 2026 from $2.8 million in Q2 2025, driven by increased headcount, legal, and IT costs.

• Cash and cash equivalents were $55.0 million as of June 30, 2026, prior to IPO proceeds.

• Non-cash stock-based compensation was $2.1 million for Q2 2026.

Outlook and guidance

• Cash and IPO proceeds are expected to fund operations into 2029, but additional capital will be needed to complete clinical development and commercialization.

• Phase 3 trials for onzotrigine and Phase 2 for LTG-321 are key near-term milestones; topline data for both expected in the second half of 2027.

• Company plans to opportunistically raise additional capital and may pursue strategic collaborations.